Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- KRYS
- Price
- 132.46
- Stock movement up
- +0.37 (0.28%)
- Company name
- Krystal Biotech Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 3.81B
- Ent value
- 3.53B
- Price/Sales
- 15.77
- Price/Book
- 4.30
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 72.74
- Forward P/E
- 19.58
- PEG
- -
- EPS growth
- -
- 1 year return
- -25.46%
- 3 year return
- 37.95%
- 5 year return
- 23.84%
- 10 year return
- -
Last updated: 2025-06-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
KRYS does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 72.74 |
| Price to OCF | 60.14 |
| Price to FCF | 65.61 |
| Price to EBITDA | 51.61 |
| EV to EBITDA | 47.85 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 15.77 |
| Price to Book | 4.30 |
| EV to Sales | 14.62 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 28.76M |
| EPS (TTM) | 1.75 |
| FCF per share (TTM) | 1.94 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 241.52M |
| Gross profit (TTM) | 220.04M |
| Operating income (TTM) | 39.95M |
| Net income (TTM) | 52.37M |
| EPS (TTM) | 1.75 |
| EPS (1y forward) | 6.77 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 91.11% |
| Operating margin (TTM) | 16.54% |
| Profit margin (TTM) | 21.68% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 373.97M |
| Net receivables | 97.30M |
| Total current assets | 713.16M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 982.32M |
| Accounts payable | 5.58M |
| Short/Current long term debt | 1.29M |
| Total current liabilities | 89.53M |
| Total liabilities | 96.47M |
| Shareholder's equity | 885.85M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 63.34M |
| Capital expenditures (TTM) | 5.28M |
| Free cash flow (TTM) | 58.06M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 5.91% |
| Return on Assets | 5.33% |
| Return on Invested Capital | 5.90% |
| Cash Return on Invested Capital | 6.54% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 132.87 |
| Daily high | 133.70 |
| Daily low | 130.17 |
| Daily Volume | 691K |
| All-time high | 213.66 |
| 1y analyst estimate | 207.78 |
| Beta | 0.82 |
| EPS (TTM) | 1.75 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| KRYS | S&P500 | |
| Current price drop from All-time high | -38.00% | -3.04% |
| Highest price drop | -53.42% | -56.47% |
| Date of highest drop | 26 Nov 2021 | 9 Mar 2009 |
| Avg drop from high | -16.52% | -11.04% |
| Avg time to new high | 18 days | 12 days |
| Max time to new high | 344 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
3.81B
Marketcap category
Mid-cap
Description
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Employees
229
Website
Investor relations
-
SEC filings
CEO
Krish S. Krishnan
Country
USA
City
Pittsburgh
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page